Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Current Deferred Revenue (2019 - 2025)

Biodesix (BDSX) has disclosed Current Deferred Revenue for 7 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue rose 47.49% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Dec 2025, up 47.49%, and an annual FY2025 reading of $1.0 million, up 47.49% over the prior year.
  • Current Deferred Revenue was $1.0 million for Q4 2025 at Biodesix, down from $2.8 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $2.8 million in Q3 2025 and bottomed at $300000.0 in Q4 2023.
  • Average Current Deferred Revenue over 5 years is $1.3 million, with a median of $1.0 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue tumbled 71.55% in 2024, then surged 300.0% in 2025.
  • Year by year, Current Deferred Revenue stood at $1.8 million in 2021, then tumbled by 45.95% to $1.0 million in 2022, then tumbled by 70.0% to $300000.0 in 2023, then soared by 126.0% to $678000.0 in 2024, then soared by 47.49% to $1.0 million in 2025.
  • Business Quant data shows Current Deferred Revenue for BDSX at $1.0 million in Q4 2025, $2.8 million in Q3 2025, and $617000.0 in Q2 2025.